Elisa Agostinetto: The proportion of patients with an actionable alteration (AA) in serial cfDNA decreases with time
Elisa Agostinetto, Clinical Research Fellow at Jules Bordet Institute in Brussels, shared a post on X/Twitter:
“Out in npj Journals Breast:
The proportion of patients with an actionable alteration (AA) in serial cfDNA decreases with time.
AA in HR+/HER2- MBC inform the selection of therapies while cfDNA in TNBC or HER2+ MBC seems less effective in guiding treatment.”
View the article attached to the post.
Source: Elisa Agostinetto/X
About OncoDaily
OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within short period of time it became one of the leading oncology media platforms globally.
OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.
The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we.”